非布司他治疗3期CKD合并无症状高尿酸血症的随机试验
本研究为随机双盲安慰剂对照试验,纳入467例3期CKD合并无症状高尿酸血症患者,干预108周。结果显示非布司他组与安慰剂组eGFR斜率无显著差异(差异0.70,95%CI -0.21至1.62,P=0.1),但非布司他可降低痛风性关节炎发生率。
要点
- 非布司他未能延缓3期CKD合并无症状高尿酸血症患者的肾功能下降。
- 非布司他组痛风性关节炎发生率显著低于安慰剂组(0.91% vs 5.86%,P=0.007)。
- 亚组分析提示无蛋白尿或血肌酐低于中位数的患者可能获益。
核心结论
- 与安慰剂相比,非布司他未能减轻3期CKD合并无症状高尿酸血症患者的肾功能下降。
研究设计与样本
- 随机、双盲、安慰剂对照试验,纳入日本55家医疗机构的467例3期CKD合并无症状高尿酸血症患者,1:1随机接受非布司他或安慰剂治疗108周。
主要发现
- 非布司他组平均eGFR斜率为0.23±5.26 mL/min/1.73m2/年,安慰剂组为-0.47±4.48 mL/min/1.73m2/年,差异0.70(95%CI -0.21至1.62,P=0.1)。
- 亚组分析显示非布司他在无蛋白尿患者(P=0.005)和血肌酐低于中位数患者(P=0.009)中有显著获益。
- 痛风性关节炎发生率非布司他组为0.91%,安慰剂组为5.86%,差异显著(P=0.007)。
- 未观察到非布司他特异性不良事件。
临床怎么用
- 对于3期CKD合并无症状高尿酸血症患者,非布司他不应以延缓肾功能下降为目的常规使用。
- 非布司他可考虑用于降低痛风性关节炎风险,但需权衡利弊。
局限性
- GFR为估算值而非实测值。
- 排除了4期和5期CKD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Epidemiologic and clinical studies have suggested that urate-lowering therapy may slow the progression of chronic kidney disease (CKD). However, definitive evidence is lacking. STUDY DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING & PARTICIPANTS: 467 patients with stage 3 CKD and asymptomatic hyperuricemia at 55 medical institutions in Japan. INTERVENTION: Participants were randomly assigned in a 1:1 ratio to receive febuxostat or placebo for 108 weeks. OUTCOMES: The primary end point was the slope (in mL/min/1.73m2 per year) of estimated glomerular filtration rate (eGFR). Secondary end points included changes in eGFRs and serum uric acid levels at 24, 48, 72, and 108 weeks of follow-up and the event of doubling of serum creatinine level or initiation of dialysis therapy. RESULTS: Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. There was no significant difference in mean eGFR slope between the febuxostat (0.23±5.26mL/min/1.73m2 per year) and placebo (-0.47±4.48mL/min/1.73m2 per year) groups (difference, 0.70; 95% CI, -0.21 to 1.62; P=0.1). Subgroup analysis demonstrated a significant benefit from febuxostat in patients without proteinuria (P=0.005) and for whom serum creatinine concentration was lower than the median (P=0.009). The incidence of gouty arthritis was significantly lower (P=0.007) in the febuxostat group (0.91%) than in the placebo group (5.86%). Adverse events specific to febuxostat were not observed. LIMITATIONS: GFR was estimated rather than measured, and patients with stages 4 and 5 CKD were excluded. CONCLUSIONS: Compared to placebo, febuxostat did not mitigate the decline in kidney function among patients with stage 3 CKD and asymptomatic hyperuricemia. FUNDING: Funded by Teijin Pharma Limited. TRIAL REGISTRATION: Registered at the UMIN (University Hospital Medical Information Network) Clinical Trials Registry with study number UMIN000008343.
引用
- Kimura K, Hosoya T, Uchida S, et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis. 2018. PMID: 30177485. doi:10.1053/j.ajkd.2018.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。